295 related articles for article (PubMed ID: 32010920)
1. The European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study: Baseline Data Release V500.0.
Ritchie CW; Muniz-Terrera G; Kivipelto M; Solomon A; Tom B; Molinuevo JL
J Prev Alzheimers Dis; 2020; 7(1):8-13. PubMed ID: 32010920
[TBL] [Abstract][Full Text] [Related]
2. European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS): study protocol.
Solomon A; Kivipelto M; Molinuevo JL; Tom B; Ritchie CW;
BMJ Open; 2019 Feb; 8(12):e021017. PubMed ID: 30782589
[TBL] [Abstract][Full Text] [Related]
3. Prescreening for European Prevention of Alzheimer Dementia (EPAD) trial-ready cohort: impact of AD risk factors and recruitment settings.
Vermunt L; Muniz-Terrera G; Ter Meulen L; Veal C; Blennow K; Campbell A; Carrié I; Delrieu J; Fauria K; Huesa Rodríguez G; Ingala S; Jenkins N; Molinuevo JL; Ousset PJ; Porteous D; Prins ND; Solomon A; Tom BD; Zetterberg H; Zwan M; Ritchie CW; Scheltens P; Luscan G; Brookes AJ; Visser PJ;
Alzheimers Res Ther; 2020 Jan; 12(1):8. PubMed ID: 31907067
[TBL] [Abstract][Full Text] [Related]
4. The European Prevention of Alzheimer's Dementia Programme: An Innovative Medicines Initiative-funded partnership to facilitate secondary prevention of Alzheimer's disease dementia.
Saunders S; Gregory S; Clement MHS; Birck C; van der Geyten S; Ritchie CW
Front Neurol; 2022; 13():1051543. PubMed ID: 36484017
[TBL] [Abstract][Full Text] [Related]
5. European Prevention of Alzheimer's Dementia Registry: Recruitment and prescreening approach for a longitudinal cohort and prevention trials.
Vermunt L; Veal CD; Ter Meulen L; Chrysostomou C; van der Flier W; Frisoni GB; Guessous I; Kivipelto M; Marizzoni M; Martinez-Lage P; Molinuevo JL; Porteous D; Ritchie K; Scheltens P; Ousset PJ; Ritchie CW; Luscan G; Brookes AJ; Visser PJ
Alzheimers Dement; 2018 Jun; 14(6):837-842. PubMed ID: 29604264
[TBL] [Abstract][Full Text] [Related]
6. Association between Longitudinal Cerebrospinal Fluid Alzheimer's Biomarkers and the Lifestyle for Brain Health (LIBRA) Index: Findings from the European Prevention of Alzheimer's Dementia Cohort Study (EPAD LCS).
Saunders TS; Protsiv M; Jenkins ND; Solomon A; Blennow K; Ritchie C; Muniz-Terrera G
J Prev Alzheimers Dis; 2023; 10(3):543-550. PubMed ID: 37357296
[TBL] [Abstract][Full Text] [Related]
7. Associations Between Multimorbidity and Cerebrospinal Fluid Amyloid: A Cross-Sectional Analysis of the European Prevention of Alzheimer's Dementia (EPAD) V500.0 Cohort.
Stirland LE; Russ TC; Ritchie CW; Muniz-Terrera G;
J Alzheimers Dis; 2019; 71(2):703-711. PubMed ID: 31424394
[TBL] [Abstract][Full Text] [Related]
8. Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project.
Ritchie CW; Molinuevo JL; Truyen L; Satlin A; Van der Geyten S; Lovestone S;
Lancet Psychiatry; 2016 Feb; 3(2):179-86. PubMed ID: 26683239
[TBL] [Abstract][Full Text] [Related]
9. Cognitive Functions as Predictors of Alzheimer's Disease Biomarker Status in the European Prevention of Alzheimer's Dementia Cohort.
Terrera GM; Harrison JE; Ritchie CW; Ritchie K
J Alzheimers Dis; 2020; 74(4):1203-1210. PubMed ID: 32144988
[TBL] [Abstract][Full Text] [Related]
10. The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD): Experience from the First 3 Years.
Walter S; Langford OG; Clanton TB; Jimenez-Maggiora GA; Raman R; Rafii MS; Shaffer EJ; Sperling RA; Cummings JL; Aisen PS
J Prev Alzheimers Dis; 2020; 7(4):234-241. PubMed ID: 32920625
[TBL] [Abstract][Full Text] [Related]
11. Recommended cognitive outcomes in preclinical Alzheimer's disease: Consensus statement from the European Prevention of Alzheimer's Dementia project.
Ritchie K; Ropacki M; Albala B; Harrison J; Kaye J; Kramer J; Randolph C; Ritchie CW
Alzheimers Dement; 2017 Feb; 13(2):186-195. PubMed ID: 27702619
[TBL] [Abstract][Full Text] [Related]
12. The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow.
Lorenzini L; Ingala S; Wink AM; Kuijer JPA; Wottschel V; Dijsselhof M; Sudre CH; Haller S; Molinuevo JL; Gispert JD; Cash DM; Thomas DL; Vos SB; Prados F; Petr J; Wolz R; Palombit A; Schwarz AJ; Chételat G; Payoux P; Di Perri C; Wardlaw JM; Frisoni GB; Foley C; Fox NC; Ritchie C; Pernet C; Waldman A; Barkhof F; Mutsaerts HJMM;
Neuroimage Clin; 2022; 35():103106. PubMed ID: 35839659
[TBL] [Abstract][Full Text] [Related]
13. Disease Modelling of Cognitive Outcomes and Biomarkers in the European Prevention of Alzheimer's Dementia Longitudinal Cohort.
Howlett J; Hill SM; Ritchie CW; Tom BDM
Front Big Data; 2021; 4():676168. PubMed ID: 34490422
[TBL] [Abstract][Full Text] [Related]
14. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
[TBL] [Abstract][Full Text] [Related]
15. Ethical Issues in the Development of Readiness Cohorts in Alzheimer's Disease Research.
Milne R; Bunnik E; Tromp K; Bemelmans S; Badger S; Gove D; Maman M; Schermer M; Truyen L; Brayne C; Richard E
J Prev Alzheimers Dis; 2017; 4(2):125-131. PubMed ID: 29186282
[TBL] [Abstract][Full Text] [Related]
16. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
17. Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer's Disease (TRC-PAD).
Walter S; Clanton TB; Langford OG; Rafii MS; Shaffer EJ; Grill JD; Jimenez-Maggiora GA; Sperling RA; Cummings JL; Aisen PS
J Prev Alzheimers Dis; 2020; 7(4):219-225. PubMed ID: 32920623
[TBL] [Abstract][Full Text] [Related]
18. Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials.
Langford O; Raman R; Sperling RA; Cummings J; Sun CK; Jimenez-Maggiora G; Aisen PS; Donohue MC
J Prev Alzheimers Dis; 2020; 7(4):213-218. PubMed ID: 32920622
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
20. Cohort-Specific Optimization of Models Predicting Preclinical Alzheimer's Disease, to Enhance Screening Performance in the Middle of Preclinical Alzheimer's Disease Clinical Studies.
Sato K; Mano T; Ihara R; Suzuki K; Niimi Y; Toda T; Iwatsubo T; Iwata A
J Prev Alzheimers Dis; 2021; 8(4):503-512. PubMed ID: 34585226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
